Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H17N2O2S.Na |
Molecular Weight | 264.32 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCC(C)C1(CC)C(=O)NC(=S)[N-]C1=O
InChI
InChIKey=AWLILQARPMWUHA-UHFFFAOYSA-M
InChI=1S/C11H18N2O2S.Na/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1
Sodium thiopental (also known as Sodium Pentothal, thiopental) was discovered in 1930s by investigators working for Abbott Laboratories. Thiopental sodium was used for the induction of general anesthesia and is used as an adjunct to provide hypnosis during balanced anesthesia with other anesthetic agents, including analgesics and muscle relaxants. Thiopental sodium was also used as an adjunct for control of convulsive disorders of various etiology, including those caused by local anesthetics. Finally, thiopental sodium had been used to reduce the intracranial pressure in patients with increased intracranial pressure, if controlled ventilation is provided. Nevertheless, these prescriptions of drug were discontinued. In addition, this drug was banned for use in US executions. Thiopental sodium acts through the CNS with particular activity in the mesencephalic reticular activating system. It was shown, that mechanism of action of sodium thiopental via GABAA receptor. Thiopental binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18619475 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PENTOTHAL Approved UsePentothal (Thiopental Sodium for Injection) is indicated (1) as the sole anesthetic agent for brief (15 minute) procedures, (2) for induction of anesthesia prior to administration of other anesthetic agents, (3) to supplement regional anesthesia, (4) to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, (5) for the control of convulsive states during or following inhalation anesthesia, local anesthesia, or other causes, (6) in neurosurgical patients with increased intracranial pressure, if adequate ventilation is provided, and (7) for narcoanalysis and narcosynthesis in psychiatric disorders. |
Doses
Dose | Population | Adverse events |
---|---|---|
500 mg multiple, intravenous (starting) Dose: 500 mg Route: intravenous Route: multiple Dose: 500 mg Sources: |
unhealthy, 31 years (range: 19 -44 years) n = 13 Health Status: unhealthy Age Group: 31 years (range: 19 -44 years) Sex: M+F Population Size: 13 Sources: |
Other AEs: Hypothermia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypothermia | 1 patient | 500 mg multiple, intravenous (starting) Dose: 500 mg Route: intravenous Route: multiple Dose: 500 mg Sources: |
unhealthy, 31 years (range: 19 -44 years) n = 13 Health Status: unhealthy Age Group: 31 years (range: 19 -44 years) Sex: M+F Population Size: 13 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolism of thiopental-S35 and thiopental-2-C14 by a rat liver mince and identification of pentobarbital as a major metabolite. | 1955 Jul |
|
Local anesthetic-induced convulsions in man--an electroencephalographic study. | 1966 Sep-Oct |
|
Further investigation into local complications of thiopentone injection. | 1971 May |
|
Abdominal-muscle rigidity induced by morphine and nitrous oxide. | 1973 Apr |
|
Thiopentone anaphylaxis--case report. | 1975 Aug |
|
Postischemic brain oxygenation with barbiturate therapy in rats. | 1979 Aug |
|
Adverse reactions following fazadinium-thiopentone induction. | 1979 Jul-Aug |
|
Brain blood flow and metabolism after global ischemia and post-insult thiopental therapy in monkeys. | 1979 Sep-Oct |
|
Ketamine hypertension and the renin-angiotensin system. | 1983 |
|
The safety of etomidate: a new intravenous anaesthetic induction agent. | 1983 Jun |
|
Another case of grand mal seizure after fentanyl administration. | 1984 Apr |
|
Domperidone--an acute dystonic reaction. | 1985 Feb |
|
[Phlebitis of the arm caused by pentothal infusion]. | 1985 Oct-Dec |
|
Etomidate versus thiopental for induction of anesthesia. | 1985 Sep |
|
Asystole associated with vecuronium. | 1986 Aug |
|
Drug-induced arterial spasm relieved by lidocaine. Case report. | 1986 Nov |
|
Factors that influence cutaneous reactions following administration of thiopentone and atracurium. | 1988 Oct |
|
Acute macular neuroretinopathy following intravenous sympathomimetics. | 1989 |
|
[Muscular rigidity caused by alfentanil: prevention]. | 1989 Jun |
|
Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs: VII. Verapamil and thiopental. | 1989 Oct |
|
Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. | 1989 Sep |
|
Intravenous midazolam significantly enhances the lethal effect of thiopental but not that of ketamine in mice. | 2001 Dec |
|
Dual effects of melatonin on barbiturate-induced narcosis in rats. | 2001 Mar 16 |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Effect of thiopental, propofol, and etomidate on vincristine toxicity in PC12 cells. | 2002 |
|
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
Torsade de pointes and sudden death induced by thiopental and isoflurane anesthesia in dogs with cardiac electrical remodeling. | 2002 Jan |
|
Life-threatening hyperkalaemia following therapeutic barbiturate coma. | 2002 Sep |
|
Effect of sodium succinate on gas exchange in rats with barbiturate-induced coma. | 2003 Apr |
|
Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases. | 2003 Mar-Apr |
|
Seventy-four defibrillations for sotalol-induced torsades de pointes. | 2004 Jul-Aug |
|
Effects of different anaesthetic agents on immune cell function in vitro. | 2005 Aug |
|
Propofol and thiopental for refractory status epilepticus in children. | 2005 Aug 23 |
|
Intravenous propofol precipitates the hypotension induced by inadvertent epidural thiopental injection. | 2006 Dec |
|
Synergism of isothermal regimen and sodium succinate in experimental therapy of barbiturate coma. | 2006 Jul |
|
Fulminant hyperammonaemia induced by thiopental coma in rats. | 2006 Jul 25 |
|
Glutamate binding is altered in hippocampus and cortex of Wistar rats after pilocarpine-induced Status Epilepticus. | 2007 Aug 31 |
|
Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. | 2007 Sep |
|
Thiopental protects human T lymphocytes from apoptosis in vitro via the expression of heat shock protein 70. | 2008 Apr |
|
Thiopental pharmacokinetics in newborn infants: a case report of overdose. | 2009 Oct |
|
Incidence of postoperative delirium is high even in a population without known risk factors. | 2014 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/14338
Thiopental Sodium 500 mg Injection is administered intravenously normally as a 2.5% w/v (500 mg in 20 ml) solution. On occasions it may be administered as a 5% w/v solution (500 mg in 10 ml).
The intravenous injection preparation should be used after reconstitution of the sterile powder with Water for Injections, usually to produce a 2.5% w/v solution and this should be discarded after seven hours.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18619475
In cultured spinal cord slices from mice, thiopental reduced action potential activity with an EC50 of 16.6 ± 2.4 μM. Recordings of GABAA and glycine receptor-mediated inhibitory currents indicated that the effect was largely mediated by GABAA receptors and that glycine receptors were not relevant targets. Specifically, 20 μM thiopental prolonged the decay time of spontaneous GABAergic inhibitory postsynaptic currents (sIPSCs) more than twofold. Although this prolongation of decay time increased the inhibitory charge per sIPSC the concomitant strong reduction of sIPSC frequency resulted in less inhibitory current entering the neurons via this route. However, 20 μM thiopental also induced a tonic current of 30 ± 10 pA, mediated by GABAA receptors; 50 μM thiopental nearly abolished sIPSC activity but augmented tonic currents to 69 ± 14 pA.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
||
|
CFR |
21 CFR 522.2444
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
||
|
DEA NO. |
2100
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
||
|
CFR |
21 CFR 522.2444A
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
||
|
CFR |
21 CFR 522.2444B
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
102166
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
THIOPENTAL SODIUM
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | Description: A yellowish white powder; odour, characteristic. Solubility: Freely soluble in water and ethanol (~750 g/l) TS; practically insoluble in ether R. Category: General anaesthetic. Storage: Thiopental sodium should be kept in a tightly closed container, protected from light. Additional information: Thiopental sodium is hygroscopic. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Requirements: Thiopental sodium contains not less than 97.0% and not more than the equivalent of 102.0% of C11H17N2NaO2S, calculated with reference to the dried substance. | ||
|
71-73-8
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
DTXSID1021744
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
200-763-1
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
m10773
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
12832575
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
433
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
SUB10981MIG
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
282416
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT001409
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
100000091816
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
SUB04816MIG
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL441
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
Sodium thiopental
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
9561
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
759557
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
49Y44QZL70
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY | |||
|
C66599
Created by
admin on Fri Dec 15 16:04:43 GMT 2023 , Edited by admin on Fri Dec 15 16:04:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD